The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial
Open accessAbstract
OBJECTIVES: Open-labelled clinical trials suggested that low-dose IL-2 might be effective in treatment of systemic lupus erythematosus (SLE). A double-blind and placebo-controlled trial is required to formally evaluate the safety and efficacy of low-dose IL-2 therapy. METHODS: A randomised, double-blind and placebo-controlled clinical trial was designed to treat 60 patients with active SLE. These patients received either IL-2 (n=30) or placebo (n=30) with standard treatment for 12 weeks, and were followed up for additional 12 weeks. IL-2 at a dose of 1 million IU or placebo was administered subcutaneously every other day for 2 weeks and followed by a 2-week break as one treatment cycle. The primary endpoint was the SLE Responder Index-4 (SRI-4) at week 12. The secondary endpoints were other clinical responses, safety and dynamics of immune cell subsets. RESULTS: At week 12, the SRI-4 response rates were 55.17% and 30.00% for IL-2 and placebo, respectively (p=0.052). At week 24, the SRI-4 response rate of IL-2 group was 65.52%, compared with 36.67% of the placebo group (p=0.027). The primary endpoint was not met at week 12. Low-dose IL-2 treatment resulted in 53.85% (7/13) complete remission in patients with lupus nephritis, compared with 16.67% (2/12) in the placebo group (p=0.036). No serious infection was observed in the IL-2 group, but two in placebo group. Besides expansion of regulatory T cells, low-dose IL-2 may also sustain cellular immunity with enhanced natural killer cells. CONCLUSIONS: Low-dose IL-2 might be effective and tolerated in treatment of SLE. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov Registries (NCT02465580 and NCT02932137).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
(2016) · Diagnostic Imaging: Brain · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990
Tsokos, G. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100359 · Cited by 2,736
IL-2: The First Effective Immunotherapy for Human Cancer
Rosenberg, S. A. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1490019 · Cited by 1,289
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
Koreth, J., Matsuoka, K.-I., Kim, H. T., McDonough, S. M., Bindra, B., Alyea, E. P., Armand, P., Cutler, C., Ho, V. T., Treister, N. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108188 · Cited by 1,119
Regulatory T-Cell Responses to Low-Dose Interleukin-2 in HCV-Induced Vasculitis
Saadoun, D., Rosenzwajg, M., Joly, F., Six, A., Carrat, F., Thibault, V., Sene, D., Cacoub, P., & Klatzmann, D. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105143 · Cited by 762
The promise of low-dose interleukin-2 therapy for autoimmune and inflammatory diseases
Klatzmann, D., & Abbas, A. K. (2015) · Nature Reviews Immunology · doi:10.1038/nri3823 · Cited by 636
He, J., Zhang, X., Wei, Y., Sun, X., Chen, Y., Deng, J., Jin, Y., Gan, Y., Hu, X., Jia, R., et al. (2016) · Nature Medicine · doi:10.1038/nm.4148 · Cited by 572
Self-citationNovel evidence‐based systemic lupus erythematosus responder index
Furie, R. A., Petri, M. A., Wallace, D. J., Ginzler, E. M., Merrill, J. T., Stohl, W., Chatham, W. W., Strand, V., Weinstein, A., Chevrier, M. R., et al. (2009) · Arthritis Care & Research · doi:10.1002/art.24698 · Cited by 490
Matsuoka, K.-I., Koreth, J., Kim, H. T., Bascug, G., McDonough, S., Kawano, Y., Murase, K., Cutler, C., Ho, V. T., Alyea, E. P., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005265 · Cited by 468
Cited by
Update οn the diagnosis and management of systemic lupus erythematosus
Fanouriakis, A., Tziolos, N., Bertsias, G., & Boumpas, D. T. (2021) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-218272 · Cited by 753
The Main Challenges in Systemic Lupus Erythematosus: Where Do We Stand?
Piga, M., & Arnaud, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020243 · Cited by 99
Treg cell therapy: How cell heterogeneity can make the difference
Giganti, G., Atif, M., Mohseni, Y., Mastronicola, D., Grageda, N., Povoleri, G. A., Miyara, M., & Scottà, C. (2021) · European Journal of Immunology · doi:10.1002/eji.201948131 · Cited by 82
Wang, Y., Zheng, J., Islam, M. S., Yang, Y., Hu, Y., & Chen, X. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.59534 · Cited by 71
Self-citation
Metadata
- Authors
- He, J., Zhang, R., Shao, M., Zhao, X., Miao, M., Chen, J., Liu, J., Zhang, X., Zhang, X., Jin, Y., Wang, Y., Zhang, S., Zhu, L., Jacob, A., Jia, R., You, X., Li, X., Li, C., Zhou, Y., Yang, Y., Ye, H., Liu, Y., Su, Y., Shen, N., Alexander, J., Guo, J., Ambrus, J., Lin, X., Yu, D., Sun, X., & Li, Z.
- Venue
- Annals of the Rheumatic Diseases
- Publisher
- Elsevier BV
- Published
- 2020-01
- Volume
- 79
- Issue
- 1
- Pages
- 141-149
- ISSN
- 0003-4967 (ISSN-L)
- OpenAlex
- W2973404796
- Cited by
- 345
- References
- 33
- FWCI
- 26.86
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. https://app.cochat.ai/papers/10.1136/annrheumdis-2019-215396
- The paper
- He, J., Zhang, R., Shao, M., Zhao, X., Miao, M., Chen, J., Liu, J., Zhang, X., Zhang, X., Jin, Y., Wang, Y., Zhang, S., Zhu, L., Jacob, A., Jia, R., You, X., Li, X., Li, C., Zhou, Y., . . . Li, Z. (2020). Efficacy and safety of low-dose IL-2 in the treatment of systemic lupus erythematosus: a randomised, double-blind, placebo-controlled trial. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2019-215396
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.